FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

VA Blakesley

Research Profile

Chemicals & Drugs

Anatomy

3T3 Cells

Living Beings

Phenomena

Phosphorylation

Physiology

Disorders

Cell Transformation, Neoplastic

Concepts & Ideas

Molecular Sequence Data

Co-author Network

Publications

TOP 3
Derek Le Roith; M Karas; Shoshana Yakar; B H Qu; Y Wu; VA Blakesley
The role of the insulin-like growth factors in cancer.
Y Okubo; VA Blakesley; Bethel Stannard; J Silvio Gutkind; Derek Le Roith
Insulin-like growth factor-I inhibits the stress-activated protein kinase/c-Jun N-terminal kinase.
VA Blakesley; AP Koval; Bethel Stannard; AG Scrimgeour; Derek LeRoith
Replacement of tyrosine 1251 in the carboxyl terminus of the insulin-like growth factor-I receptor disrupts the actin cytoskeleton and inhibits proliferation and anchorage-independent growth.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of VA Blakesley (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

1999: Derek Le Roith; M Karas; Shoshana Yakar; B H Qu; Y Wu; VA Blakesley
The role of the insulin-like growth factors in cancer.
The Israel Medical Association journal : IMAJ 1999;1(1):25-30.
1998: Y Okubo; VA Blakesley; Bethel Stannard; J Silvio Gutkind; Derek Le Roith
Insulin-like growth factor-I inhibits the stress-activated protein kinase/c-Jun N-terminal kinase.
The Journal of biological chemistry 1998;273(40):25961-6.
1998: VA Blakesley; AP Koval; Bethel Stannard; AG Scrimgeour; Derek LeRoith
Replacement of tyrosine 1251 in the carboxyl terminus of the insulin-like growth factor-I receptor disrupts the actin cytoskeleton and inhibits proliferation and anchorage-independent growth.
The Journal of biological chemistry 1998;273(29):18411-22.
1998: A A Butler; VA Blakesley; V Poulaki; M Tsokos; T L Wood; Derek LeRoith; V Pouliki
Stimulation of tumor growth by recombinant human insulin-like growth factor-I (IGF-I) is dependent on the dose and the level of IGF-I receptor expression.
Cancer research 1998;58(14):3021-7.
1998: Thea Kalebic; VA Blakesley; C Slade; S Plasschaert; Derek LeRoith; Lee Helman
Expression of a kinase-deficient IGF-I-R suppresses tumorigenicity of rhabdomyosarcoma cells constitutively expressing a wild type IGF-I-R.
International journal of cancer. Journal international du cancer 1998;76(2):223-7.
1998: AP Koval; VA Blakesley; Charles T Roberts; Y Zick; Derek LeRoith
Interaction in vitro of the product of the c-Crk-II proto-oncogene with the insulin-like growth factor I receptor.
The Biochemical journal 1998;330 ( Pt 2)():923-32.
1997: Jeffrey A Toretsky; Thea Kalebic; VA Blakesley; Derek LeRoith; Lee Helman
The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts.
The Journal of biological chemistry 1997;272(49):30822-7.
1997: J L Liu; VA Blakesley; J Silvio Gutkind; Derek LeRoith
The constitutively active mutant Galpha13 transforms mouse fibroblast cells deficient in insulin-like growth factor-I receptor.
The Journal of biological chemistry 1997;272(47):29438-41.
1997: A A Butler; VA Blakesley; AP Koval; R deJong; J Groffen; Derek LeRoith
In vivo regulation of CrkII and CrkL proto-oncogenes in the uterus by insulin-like growth factor-I. Differential effects on tyrosine phosphorylation and association with paxillin.
The Journal of biological chemistry 1997;272(44):27660-4.
1997: Derek Le Roith; Marcelina Parrizas; VA Blakesley
The insulin-like growth factor-I receptor and apoptosis. Implications for the aging progress.
Endocrine 1997;7(1):103-5.
1997: D L Esposito; VA Blakesley; AP Koval; AG Scrimgeour; Derek LeRoith
Tyrosine residues in the C-terminal domain of the insulin-like growth factor-I receptor mediate mitogenic and tumorigenic signals.
Endocrinology 1997;138(7):2979-88.
1997: VA Blakesley; D Beitner-Johnson; J R Van Brocklyn; S Rani; Z Shen-Orr; Bethel Stannard; Sarah Spiegel; Derek LeRoith
Sphingosine 1-phosphate stimulates tyrosine phosphorylation of Crk.
The Journal of biological chemistry 1997;272(26):16211-5.
1997: AG Scrimgeour; VA Blakesley; Bethel Stannard; Derek LeRoith
Mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways are not sufficient for insulin-like growth factor I-induced mitogenesis and tumorigenesis.
Endocrinology 1997;138(6):2552-8.
1997: Marcelina Parrizas; VA Blakesley; D Beitner-Johnson; Derek Le Roith
The proto-oncogene Crk-II enhances apoptosis by a Ras-dependent, Raf-1/MAP kinase-independent pathway.
Biochemical and biophysical research communications 1997;234(3):616-20.
1997: VA Blakesley; Bethel Stannard; Thea Kalebic; Lee Helman; Derek LeRoith
Role of the IGF-I receptor in mutagenesis and tumor promotion.
The Journal of endocrinology 1997;152(3):339-44.
1997: Derek Le Roith; VA Blakesley
The yin and the yang of the IGF system: immunological manifestations of GH resistance.
European journal of endocrinology / European Federation of Endocrine Societies 1997;136(1):33-4.
1996: VA Blakesley; A Scrimgeour; D Esposito; Derek Le Roith
Signaling via the insulin-like growth factor-I receptor: does it differ from insulin receptor signaling?
Cytokine & growth factor reviews 1996;7(2):153-9.
1996: D Beitner-Johnson; VA Blakesley; Z Shen-Orr; M Jimenez; Bethel Stannard; L M Wang; J Pierce; Derek LeRoith
The proto-oncogene product c-Crk associates with insulin receptor substrate-1 and 4PS. Modulation by insulin growth factor-I (IGF) and enhanced IGF-I signaling.
The Journal of biological chemistry 1996;271(16):9287-90.
1996: VA Blakesley; Thea Kalebic; Lee Helman; Bethel Stannard; T N Faria; Charles T Roberts; Derek LeRoith
Tumorigenic and mitogenic capacities are reduced in transfected fibroblasts expressing mutant insulin-like growth factor (IGF)-I receptors. The role of tyrosine residues 1250, 1251, and 1316 in the carboxy-terminus of the IGF-I receptor.
Endocrinology 1996;137(2):410-7.
1995: C Hernández-Sánchez; VA Blakesley; Thea Kalebic; Lee Helman; Derek LeRoith
The role of the tyrosine kinase domain of the insulin-like growth factor-I receptor in intracellular signaling, cellular proliferation, and tumorigenesis.
The Journal of biological chemistry 1995;270(49):29176-81.
1995: Bethel Stannard; VA Blakesley; H Kato; Charles T Roberts; Derek LeRoith
Single tyrosine substitution in the insulin-like growth factor I receptor inhibits ligand-induced receptor autophosphorylation and internalization, but not mitogenesis.
Endocrinology 1995;136(11):4918-24.
1995: VA Blakesley; H Kato; Charles T Roberts; Derek LeRoith
Mutation of a conserved amino acid residue (tryptophan 1173) in the tyrosine kinase domain of the IGF-I receptor abolishes autophosphorylation but does not eliminate biologic function.
The Journal of biological chemistry 1995;270(6):2764-9.
1994: T N Faria; VA Blakesley; H Kato; Bethel Stannard; Derek LeRoith; Charles T Roberts
Role of the carboxyl-terminal domains of the insulin and insulin-like growth factor I receptors in receptor function.
The Journal of biological chemistry 1994;269(19):13922-8.